Attenutin™: New Pre-Clinical Study on HMGB1 & Lung Inflammation

In a new published pre-clinical study1 (Sept 2023), Attenutin™ was evaluated for its efficacy in attenuating acute inflammatory lung injury and sepsis with results strongly suggesting that Attenutin™ could be indicated for oxidative-stress-induced lung damage protection, possibly through attenuation of increased extracellular HMGB1 accumulation.

Click HERE to download the full study.

Reducing the level of extracellular HMGB1 induced by oxidative stress and/or respiratory tract infection may have a significant impact on protecting the lungs from injury and preserving normal physiological respiratory tract functions.

HMGB1 is among the key inflammatory mediators up regulated at the time of chronic exposure to pollution. Extracellular HMGB1 accumulation in the airways and the lung plays a significant role in the pathogenesis of inflammatory lung injury.

Attenutin™ is a specially formulated, natural bioflavonoid composition, clinically proven to support mucous membrane lining of the respiratory system and healthy lung function, with a long history of safe human consumption. This is just one of the four new ingredients from US based prinicipal, Unigen Inc. added to the LEHVOSS Nutrition portfolio this year. Why not check out the others: Amlexin™, Anivestin™ and Univestin™.

For more information visit our Attenutin™ dedicated page or contact us.

Reference: Yimam, M.; Horm, T.; O’Neal, A.; Jiao, P.; Hong, M.; Brownell, L.; Jia, Q.; Lin, M.; Gauthier, A.;Wu, J.; et al. A Standardized Botanical Composition Mitigated Acute Inflammatory Lung Injury and Reduced Mortality through Extracellular HMGB1 Reduction. Molecules 2023, 28, 6560. https://